首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III open‐label 2:1 randomized treat‐to‐target trial

【2h】

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III open‐label 2:1 randomized treat‐to‐target trial

机译：地格曲胰岛素/门冬胰岛素与双相门冬胰岛素30在中国2型糖尿病成年人中的疗效和安全性：III期开放标签2：1随机针对治疗的试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimsTo assess the efficacy and safety of twice‐daily insulin degludec/insulin aspart (IDegAsp) versus biphasic insulin aspart 30 (BIAsp 30) twice daily, both ± metformin, in Chinese adults (N = 543) with type 2 diabetes (T2D) inadequately controlled on premixed/self‐mixed or basal insulin ± metformin.

机译：目的评估每日两次两次地格胰岛素/门冬胰岛素（IDegAsp）与双相门冬胰岛素30（BIAsp 30）每天两次，均以±二甲双胍治疗在2型糖尿病（T2D）中国成年人中（N = 543）的有效性和安全性通过预混合/自混合或基础胰岛素±二甲双胍控制。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Wenying Yang; Jianhua Ma; Tianpei Hong; Ming Liu; Heng Miao; Yongde Peng; Changjiang Wang; Xiangjin Xu; Tao Yang; Anne M. Nielsen; Lili Pan; Weihong Liu; Weigang Zhao;
展开▼
作者单位

展开▼
年(卷),期 -1(21),7
年度 -1
页码 1652–1660
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
biphasic insulin aspart insulin aspart insulin degludec insulin treatment intensive insulin therapy type 2 diabetes;

机译：门冬胰岛素;门冬胰岛素;地格曲胰岛素;胰岛素治疗;强化胰岛素治疗;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial [J] . Yang Wenying, Ma Jianhua, Hong Tianpei, Diabetes, obesity & metabolism . 2019,第7期

机译：胰岛素Degludec /胰岛素Aspart的疗效和安全性与2型糖尿病的中国成人双相胰岛素Aspart 30：III期，开放标签，2：1随机治疗，目标试验
2. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan [J] . Hassanein Mohamed, Echtay Akram Salim, Malek Rachid, Diabetes research and clinical practice . 2018,第期

机译：原文：胰岛素Degludec /胰岛素Aspart的疗效和安全性分析与双相胰岛素Aspart 30：2型糖尿病患者患者的3，多期，国际，开放标签，随机治疗对目标试验
3. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trial [J] . Fulcher,G.R., Christiansen,J.S., Bantwal,G., Diabetes care . 2014,第8期

机译：未控制，经胰岛素治疗的2型糖尿病中地格曲松/门冬胰岛素和双相门冬胰岛素30的比较：A期3a，随机，靶向治疗
4. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator^* [C] . Roberto Visentin, Michele Schiavon, Clemens Giegerich, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2018

机译：长效胰岛素在糖尿病治疗中的作用：采用UVA / Padova 1型糖尿病模拟器的Silico临床试验^*
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. 28‐week randomized multicenter open‐label parallel‐group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice‐daily injections vs twice‐daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes [O] . Takashi Kadowaki, Tomoyuki Nishida, Kohei Kaku 2010

机译：28周随机多中心开放标签平行分组的III期临床试验研究天冬两次注射天冬胰岛素30次每天两次与天冬两次注射天冬胰岛素30天两次两次在2型糖尿病患者中的疗效和安全性
7. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open‐label, 2:1 randomized, treat‐to‐target trial [O] . Wenying Yang, Jianhua Ma, Tianpei Hong, 2019

机译：胰岛素Degludec /胰岛素Aspart的疗效和安全性与2型糖尿病的中国成人双相胰岛素Aspart 30：III期，开放标签，2：1随机治疗，目标试验

Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III open‐label 2:1 randomized treat‐to‐target trial

摘要

著录项

相似文献

相关主题

期刊订阅